NASDAQ$CRBU
Caribou Biosciences Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Caribou Biosciences Inc reported Q2 2025 financial results with licensing revenue of $2.7 million and a net loss of $54.1 million.
The company recorded licensing and collaboration revenue of $2.7 million for the three months ended June 30, 2025. Operating expenses totaled $50.2 million, including $12.2 million in impairment charges related to strategic pipeline prioritization. The net loss widened to $54.1 million amid restructuring and asset impairments.
- Q2 revenue declined to $2.7 million from $3.5 million in Q2 2024 due to lower licensing activity.
- R&D expenses decreased to $27.7 million as a result of workforce reductions and program discontinuations.
- Impairment charges of $12.2 million and equity investment impairment of $9.2 million significantly impacted results.
- Cash and cash equivalents stood at $25.2 million with total assets at $220.9 million at quarter end.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$2.67M
Revenue by segment
Caribou Biosciences · $3.76M total across 1 segment · Q2 2023
- Licensing & collaboration$3.76M-10.6%100.0%
Forward guidance
Company is focusing resources on CB-010 and CB-011 following pipeline prioritization and workforce reduction.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro